Block Listing Interim Review

Summary by AI ^BETAClose X

CVS Group plc has provided an interim review of its block listing arrangements for the period from July 12, 2025, to January 12, 2026. During this period, 599 ordinary shares were issued under the CVS Group SAYE Plan, reducing the unallotted balance to 337,366 shares, while the CVS Long Term Incentive Plan had no shares issued, maintaining its unallotted balance at 68,393 shares. The company originally listed 350,000 ordinary shares for the SAYE plan on December 30, 2021, and 120,000 ordinary shares for the LTIP on May 15, 2023.

Disclaimer*

CVS Group plc

12 January 2026

CVS Group plc

("CVS" or the "Company")

Block Listing Interim Review

CVS, the UK's listed veterinary group and a leading provider of veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").

Name of the company:		CVS Group plc
Name of relevant scheme:		1. CVS Group SAYE Plan; and 2. CVS Long Term Incentive Plan
Period of return:	From:	12 July 2025	To:	12 January 2026
Balance of unallotted securities under scheme(s) from previous return:		1. 337,965 2. 68,393
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. Nil 2. Nil
Less: Number of securities issued / allotted under scheme(s) during period:		1. 599 2. Nil
Equals: Balance under scheme(s) not yet issued / allotted at end of period:		1. 337,366 2. 68,393
Number and class of securities originally listed and the date of admission:		1. 350,000 Ordinary Shares admitted on 30 December 2021 2. 120,000 Ordinary Shares admitted on 15 May 2023

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR)

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END